Following a day of meetings with Pacira's management, Jefferies analyst David Steinberg reiterated a Buy rating and $109 per share price target on the specialty pharmaceutical company, according to a StreetInsider.com article.
Mr. Steinberg stated, "Pacira remains one of the rare 'hyper growth' stories in life sciences — with stellar execution leading to Exparel annualizing at $180M (just 1.6 percent share) after nine quarters."
Pacira Pharmaceuticals' shares closed yesterday at $101.85.